Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
25.7M
-
Number of holders
-
100
-
Total shares
-
22.9M
-
Shares change
-
+559K
-
Total reported value, excl. options
-
$464M
-
Value change
-
+$8.43M
-
Put/Call ratio
-
2.77
-
Number of buys
-
57
-
Number of sells
-
-34
-
Price
-
$20.28
Significant Holders of Tourmaline Bio, Inc. - Common Stock, $0.0001 par value per share (TRML) as of Q4 2024
115 filings reported holding TRML - Tourmaline Bio, Inc. - Common Stock, $0.0001 par value per share as of Q4 2024.
Tourmaline Bio, Inc. - Common Stock, $0.0001 par value per share (TRML) has 100 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 22.9M shares
of 25.7M outstanding shares and own 88.96% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (2.54M shares), Avoro Capital Advisors LLC (2.22M shares), BlackRock, Inc. (1.8M shares), TCG Crossover Management, LLC (1.48M shares), Pfizer Inc (1.27M shares), VANGUARD GROUP INC (1.11M shares), Blue Owl Capital Holdings LP (1.08M shares), JENNISON ASSOCIATES LLC (846K shares), STATE STREET CORP (800K shares), and Qiming U.S. Ventures Management, LLC (742K shares).
This table shows the top 100 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.